See more : Yamae Group Holdings Co.,Ltd. (7130.T) Income Statement Analysis – Financial Results
Complete financial analysis of International Stem Cell Corporation (ISCO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of International Stem Cell Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- A SPAC III Acquisition Corp. (ASPCU) Income Statement Analysis – Financial Results
- DXP Enterprises, Inc. (DXPE) Income Statement Analysis – Financial Results
- Shenzhen Envicool Technology Co., Ltd. (002837.SZ) Income Statement Analysis – Financial Results
- Boston Scientific Corporation (BSX) Income Statement Analysis – Financial Results
- SPML Infra Limited (SPMLINFRA.NS) Income Statement Analysis – Financial Results
International Stem Cell Corporation (ISCO)
About International Stem Cell Corporation
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in North America, Asia, Europe, and internationally. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; and develops, manufactures, and markets anti-aging skincare and human cell culture products. The company's human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.79M | 8.18M | 7.18M | 7.13M | 9.47M | 11.09M | 7.46M | 7.17M | 7.55M | 7.02M | 6.15M | 4.57M | 4.53M | 1.57M | 1.12M | 502.77K | 38.76K | 2.83K | 0.00 |
| Cost of Revenue | 3.18M | 3.27M | 2.94M | 2.78M | 3.93M | 4.07M | 2.12M | 1.94M | 2.06M | 1.92M | 1.64M | 1.27M | 1.62M | 724.64K | 789.71K | 129.26K | 41.00K | 30.83K | 0.00 |
| Gross Profit | 4.61M | 4.91M | 4.24M | 4.35M | 5.54M | 7.02M | 5.33M | 5.22M | 5.50M | 5.10M | 4.50M | 3.30M | 2.91M | 843.84K | 331.46K | 373.51K | -2.23K | -28.00K | 0.00 |
| Gross Profit Ratio | 59.16% | 60.04% | 59.10% | 60.98% | 58.48% | 63.31% | 71.54% | 72.87% | 72.77% | 72.62% | 73.27% | 72.15% | 64.30% | 53.80% | 29.56% | 74.29% | -5.76% | -989.99% | 0.00% |
| Research & Development | 511.00K | 492.00K | 695.00K | 988.00K | 1.39M | 2.40M | 2.66M | 2.86M | 2.71M | 5.39M | 3.56M | 3.60M | 4.43M | 3.37M | 2.16M | 1.95M | 2.49M | 1.81M | 0.00 |
| General & Administrative | 3.51M | 3.36M | 4.08M | 4.42M | 7.20M | 5.47M | 5.21M | 4.69M | 4.72M | 5.61M | 6.03M | 7.44M | 8.36M | 7.07M | 4.84M | 3.58M | 3.09M | 3.78M | 0.00 |
| Selling & Marketing | 1.25M | 1.25M | 1.38M | 1.76M | 2.69M | 2.63M | 2.41M | 2.53M | 2.64M | 2.79M | 2.46M | 2.07M | 1.48M | 860.16K | 526.64K | 380.90K | 495.01K | 97.92K | 0.00 |
| SG&A | 4.76M | 4.60M | 5.47M | 6.18M | 9.88M | 8.10M | 7.62M | 7.22M | 7.35M | 8.39M | 8.49M | 9.51M | 9.84M | 7.93M | 5.37M | 3.96M | 3.58M | 3.88M | 8.30K |
| Other Expenses | 0.00 | -13.00K | 13.00K | 0.00 | 2.00K | 23.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 |
| Operating Expenses | 5.27M | 5.09M | 6.16M | 7.17M | 11.27M | 10.49M | 10.28M | 10.07M | 10.06M | 13.78M | 12.05M | 13.11M | 14.27M | 11.31M | 7.53M | 5.91M | 6.07M | 5.69M | 8.30K |
| Cost & Expenses | 8.45M | 8.36M | 9.10M | 9.95M | 15.20M | 14.56M | 12.40M | 12.02M | 12.12M | 15.70M | 13.69M | 14.38M | 15.89M | 12.03M | 8.32M | 6.04M | 6.11M | 5.72M | 8.30K |
| Interest Income | 0.00 | 135.00K | 128.00K | 113.00K | 77.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 27.64K | 9.23K | 1.68K | 31.74K | 22.15K | 0.00 |
| Interest Expense | 139.00K | 135.00K | 128.00K | 113.00K | 77.00K | 48.00K | 59.00K | 6.00K | 11.00K | 2.00K | 3.00K | 0.00 | 1.00K | 14.08K | 94.59K | 1.05M | 41.81K | 806.16K | 0.00 |
| Depreciation & Amortization | 194.00K | 359.00K | 551.00K | 253.00K | 285.00K | 308.00K | 326.00K | 331.00K | 472.00K | 458.00K | 464.00K | 474.00K | 494.00K | 289.09K | 205.95K | 163.06K | 135.73K | 81.66K | 0.00 |
| EBITDA | 202.00K | 22.00K | -220.00K | -2.36M | -3.90M | -1.78M | -5.68M | 186.00K | -2.15M | -12.02M | -10.01M | -9.36M | -8.68M | -9.60M | -7.47M | -5.36M | -5.89M | -5.63M | -1.23M |
| EBITDA Ratio | 2.59% | 0.27% | -22.94% | -35.98% | -57.44% | -28.34% | -61.91% | -76.04% | -54.19% | -131.38% | -115.21% | -214.87% | -239.63% | -646.82% | -622.90% | -1,067.76% | -15,351.10% | -196,306.90% | 0.00% |
| Operating Income | -663.00K | -196.00K | -1.92M | -2.82M | -5.73M | -3.47M | -4.94M | -4.85M | -4.56M | -8.68M | -7.55M | -9.81M | -11.36M | -10.46M | -7.20M | -5.53M | -6.07M | -5.72M | -8.30K |
| Operating Income Ratio | -8.51% | -2.40% | -26.77% | -39.53% | -60.47% | -31.33% | -66.28% | -67.70% | -60.44% | -123.70% | -122.76% | -214.87% | -250.55% | -667.02% | -642.09% | -1,100.53% | -15,668.20% | -202,111.78% | 0.00% |
| Total Other Income/Expenses | 532.00K | -148.00K | 1.02M | 94.00K | 1.46M | 1.34M | -1.13M | 3.77M | 1.93M | -3.80M | -2.93M | -18.00K | 2.18M | 559.35K | -573.72K | -1.04M | 2.74K | -866.51K | -82.87K |
| Income Before Tax | -131.00K | -331.00K | -899.00K | -2.72M | -4.27M | -2.13M | -6.07M | -1.08M | -2.64M | -12.48M | -10.48M | -9.83M | -9.17M | -9.90M | -7.77M | -6.57M | -6.07M | -6.58M | 0.00 |
| Income Before Tax Ratio | -1.68% | -4.05% | -12.53% | -38.22% | -45.03% | -19.22% | -81.40% | -15.06% | -34.90% | -177.83% | -170.47% | -215.31% | -202.36% | -631.36% | -693.27% | -1,307.02% | -15,661.14% | -232,752.02% | 0.00% |
| Income Tax Expense | 0.00 | 135.00K | 141.00K | 113.00K | 79.00K | 1.39M | 59.00K | 6.00K | 11.00K | 2.00K | 3.00K | 1.50M | 0.00 | 14.08K | 94.59K | 1.05M | 1.10K | 1.70K | 8.30K |
| Net Income | -131.00K | -466.00K | -1.04M | -2.84M | -4.34M | -2.13M | -6.07M | -1.08M | -2.64M | -12.48M | -10.48M | -9.83M | -9.17M | -9.90M | -7.77M | -6.57M | -6.07M | -6.58M | -8.30K |
| Net Income Ratio | -1.68% | -5.70% | -14.49% | -39.80% | -45.86% | -19.22% | -81.40% | -15.06% | -34.90% | -177.83% | -170.47% | -215.31% | -202.36% | -631.36% | -693.27% | -1,307.02% | -15,663.97% | -232,812.13% | 0.00% |
| EPS | -0.02 | -0.06 | -0.13 | -0.38 | -0.58 | -0.33 | -1.46 | -0.34 | -1.33 | -9.71 | -12.77 | -17.16 | -17.79 | -21.60 | -25.12 | -27.11 | -25.76 | -42.68 | -0.07 |
| EPS Diluted | -0.02 | -0.06 | -0.13 | -0.38 | -0.58 | -0.33 | -1.46 | -0.34 | -1.29 | -9.71 | -12.77 | -17.16 | -17.79 | -21.60 | -25.12 | -27.11 | -25.76 | -42.68 | -0.07 |
| Weighted Avg Shares Out | 8.00M | 8.00M | 7.83M | 7.54M | 7.51M | 6.39M | 4.16M | 3.17M | 1.98M | 1.29M | 820.59K | 572.91K | 515.49K | 458.44K | 309.47K | 242.40K | 235.76K | 154.25K | 124.68K |
| Weighted Avg Shares Out (Dil) | 8.00M | 8.00M | 7.83M | 7.54M | 7.51M | 6.39M | 4.16M | 3.19M | 2.04M | 1.29M | 820.63K | 572.94K | 515.49K | 458.44K | 309.47K | 242.40K | 235.76K | 154.25K | 124.68K |
Brown-Forman Announces Sale of Cooperage in Alabama
Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.
Source: https://incomestatements.info
Category: Stock Reports